Avila Therapeutics Presents Data on AVL-292, a Selective Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of B Cell Cancers at the 2011 American Society of Hematology Annual Meeting
12/12/2011 11:10:23 AM
BEDFORD, Mass.--(BUSINESS WIRE)--Avila Therapeutics, Inc., announced today the presentation of clinical and preclinical data for AVL-292, a highly selective Bruton’s tyrosine kinase (Btk) inhibitor, at the 2011 American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, CA. Avila presented data on the safety and pharmacology of AVL-292 from the first two patient cohorts from the ongoing Phase 1b clinical study of AVL-292 in B cell cancers.
comments powered by